Is Zimmer Biomet (ZBH) overvalued or fairly valued?

MarketChacha shows Zimmer Biomet's valuation in context — a trailing P/E of about 23.3, a forward P/E of about 10.8, a price-to-book of about 1.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Zimmer Biomet's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.81×) from reported figures — education, not a rating.

What is Zimmer Biomet's revenue?

Zimmer Biomet reported revenue of $8.2B for FY2025, with net profit of $705.1M, per official filings.

What is the share price of Zimmer Biomet (ZBH)?

Zimmer Biomet last traded at $97.23 (-0.6% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Zimmer Biomet

ZBH · NYSE · Healthcare · United States

Snapshot

TickerZBH

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees17,000

HeadquartersWarsaw, United States

Websitewww.zimmerbiomet.com

Filings tracked18

About Zimmer Biomet

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Who owns it

Insiders0.2%
Institutions99.8%
Public & other0.0%

1,262 institutional holders

Ownership breakdown from public market data.

Top holders

Dodge & Cox Inc.12.34%
Blackrock Inc.8.19%
Harris Associates L.P.6.79%
Vanguard Capital Management LLC6.71%
Capital International Investors4.78%
State Street Corporation4.65%
Vanguard Portfolio Management LLC4.54%
Price (T.Rowe) Associates Inc4.19%

Largest institutional holders — last updated 3/31/2026.

Forensic scorecard

Margin has compressed by about 5.3 points over the period — profitability is trending down.

Cash conversion1.81×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend13.8% → 8.6%

Margin has compressed by about 5.3 points over the period — profitability is trending down.

Return on equity5.6%

Latest ROE of 5.6% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 6% · PAT -17%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $2.3B · EPS 2.49

Est. earnings growth +3.0%

Next fiscal year

Rev $8.9B · EPS 9.07

Est. earnings growth +6.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$8.2B

Net margin

8.6%

ROE

5.6%

Revenue CAGR (2y)

+5.5%

Profit CAGR (2y)

-17.0%

EPS (FY2025)

3.55

Net profit (FY2025)

$705.1M

Ask MarketChacha about ZBH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$8.2B	$705.1M	3.55	8.6%	5.6%
FY2024	$7.7B	$903.8M	4.43	11.8%	7.2%
FY2023	$7.4B	$1.0B	4.88	13.8%	8.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$2.2B	$198.3M	1.03	9.1%
2026Q1	$2.1B	$238.1M	1.22	11.4%
2025Q3	$2.0B	$230.9M	1.16	11.5%
2025Q2	$2.1B	$152.8M	0.77	7.4%
2025Q1	$1.9B	$182.0M	0.91	9.5%
2024Q3	$1.8B	$249.1M	1.23	13.7%
2024Q2	$1.9B	$242.8M	1.18	12.5%
2024Q1	$1.9B	$172.4M	0.84	9.1%
2023Q3	$1.8B	$162.7M	0.77	9.3%
2023Q2	$1.9B	$209.6M	1.00	11.2%
2023Q1	$1.8B	$232.5M	1.11	12.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/5/2026
8-K — Other events, Exhibits
SEC8/5/2026material
8-K — Results of operations, Exhibits
SEC8/5/2026material
8-K — Material agreement, Termination of agreement, Material financial obligation, Exhibits
SEC6/29/2026material
8-K — Shareholder vote results, Exhibits
SEC5/27/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/12/2026material
10-Q filing
SEC5/1/2026
8-K — Results of operations, Exhibits
SEC4/28/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC4/28/2026material
10-K filing
SEC2/20/2026
8-K — Results of operations, Exhibits
SEC2/10/2026material
8-K — Executive/director change, Exhibits
SEC1/12/2026material

2025

8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K — Other events, Exhibits
SEC10/7/2025material
8-K — Other events
SEC9/4/2025material
8-K — Results of operations, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.